Physiomics plc combines systems biology with cutting-edge mathematics to develop models that streamline the drug discovery and development process. We also have extensive experience in traditional PK/ PD analysis and modelling in cancer drug development.
Physiomics is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company uses a combination of industry standard and its own proprietary Virtual Tumour modelling technologies to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs.
Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics’ senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.